Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes

Identifier:  imarina:9387301

Handle: https://hdl.handle.net/20.500.11797/imarina9387301

Authors:  Vilariño-García T; Polonio-González ML; Pérez-Pérez A; Ribalta J; Arrieta F; Aguilar M; Obaya JC; Gimeno-Orna JA; Iglesias P; Navarro J; Durán S; Pedro-Botet J; Sánchez-Margalet V

Abstract:
Diabetes mellitus (DM) is a highly prevalent disease worldwide, estimated to affect 1 in every 11 adults; among them, 90–95% of cases are type 2 diabetes mellitus. This is partly attributed to the surge in the prevalence of obesity, which has reached epidemic proportions since 2008. In these patients, cardiovascular (CV) risk stands as the primary cause of morbidity and mortality, placing a substantial burden on healthcare systems due to the potential for macrovascular and microvascular complications. In this context, leptin, an adipocyte-derived hormone, plays a fundamental role. This hormone is essential for regulating the cellular metabolism and energy balance, controlling inflammatory responses, and maintaining CV system homeostasis. Thus, leptin resistance not only contributes to weight gain but may also lead to increased cardiac inflammation, greater fibrosis, hypertension, and impairment of the cardiac metabolism. Understanding the relationship between leptin resistance and CV risk in obese individuals with type 2 DM (T2DM) could improve the management and prevention of this complication. Therefore, in this narrative review, we will discuss the evidence linking leptin with the presence, severity, and/or prognosis of obesity and T2DM regarding CV disease, aiming to shed light on the potential implications for better management and preventive strategies.